SCM
FOLD

SevenOneSeven Capital Management’s Amicus Therapeutics FOLD Stock Holding History

SevenOneSeven Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-23,989
Closed -$246K – 21
2023
Q3 		$246K Buy
23,989
+1,645
+7% +$21.2K 0.57% 42
2023
Q2 		$300K Sell
22,344
-169
-0.8% -$2K 0.67% 32
2023
Q1 		$263K Sell
22,513
-8,385
-27% -$103K 0.59% 33
2022
Q4 		$377K Buy
30,898
+1,338
+5% +$15.1K 0.81% 22
2022
Q3 		$309K Buy
+29,560
New +$329K 0.72% 31

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

SevenOneSeven Capital Management's FOLD Position: Q4 2023 in Review

SevenOneSeven Capital Management sold out of Amicus Therapeutics (FOLD) in Q4 2023, closing a stake of 23,989 shares — an estimated $246K sold.

SevenOneSeven Capital Management first reported a position in FOLD in Q3 2022 and held it in 5 quarters. The position peaked at $377K in Q4 2022. 228 funds tracked by Wall St. Rank hold FOLD as of Q4 2023.

  • SevenOneSeven Capital Management reported no remaining Amicus Therapeutics position as of Q4 2023 after selling out during the quarter.
  • SevenOneSeven Capital Management sold 23,989 Amicus Therapeutics shares in Q4 2023, an estimated $246K.
  • SevenOneSeven Capital Management first reported a position in Amicus Therapeutics in Q3 2022 and held it in 5 quarters.
  • SevenOneSeven Capital Management's Amicus Therapeutics position peaked at $377K in Q4 2022.
  • 228 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2023.

Based on SevenOneSeven Capital Management's 13F filing for Q4 2023, filed 12 Feb 2024.